Next-generation Cologuard demonstrates improved colorectal cancer sensitivity, specificity

Next-generation Cologuard exhibited improved colorectal cancer specificity and sensitivity compared with results of the FDA registrational trial that led to approval of the noninvasive screening test, its manufacturer reported.Using colonoscopy as a reference method, the prospective multicenter BLUE-C study compared the performance of multiple colorectal cancer screening tests, including Cologuard — a multitarget stool DNA test developed by Exact Sciences in partnership with Mayo Clinic — and a fecal immunochemical test.The study — which included more than 20,000 adults agedRead More